サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1123431

世界のサイケデリックス薬市場：考察と予測 (2028年まで)

Global Psychedelic Drugs Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 114 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
世界のサイケデリックス薬市場：考察と予測 (2028年まで)
出版日: 2022年09月08日
発行: QYResearch
ページ情報: 英文 114 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、サイケデリックス薬 (Psychedelic Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析：タイプ別
    • 世界のサイケデリックス薬の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Psilocybin
    • LSD
    • MDMA
    • DMT
    • Ketamine
    • Others
  • 市場：アプリケーション別
    • 世界のサイケデリックス薬の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Depressive Disorders
    • Post-Traumatic Stress Disorders
    • Substance Abuse Disorders
    • Obsessive Compulsive Disorders
    • Others
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界のサイケデリックス薬の市場展望 (2017-2028)
  • サイケデリックス薬の市場成長トレンド：地域別
    • サイケデリックス薬 市場規模：地域別: 2017 VS 2021 VS 2028
    • サイケデリックス薬の市場規模実績：地域別 (2017-2022)
    • サイケデリックス薬の市場規模予測：地域別 (2023-2028)
  • サイケデリックス薬 市場動向
    • サイケデリックス薬 業界動向
    • サイケデリックス薬 市場の促進要因
    • サイケデリックス薬 市場の課題
    • サイケデリックス薬 市場の抑制要因

第3章 競合情勢：主要企業別

  • 世界のサイケデリックス薬の上位企業：収益別
    • 世界のサイケデリックス薬の上位企業：収益別 (2017-2022)
    • 世界のサイケデリックス薬の収益シェア：企業別 (2017-2022)
  • 世界のサイケデリックス薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング：サイケデリックス薬の収益
  • 世界のサイケデリックス薬 市場集中度
    • 世界のサイケデリックス薬 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業： サイケデリックス薬の収益 2021
  • サイケデリックス薬の主要企業の本社および事業エリア
  • 主要企業 サイケデリックス薬の製品ソリューションおよびサービス
  • 市場参入時期： サイケデリックス薬 市場
  • M&A, 拡張計画

第4章 サイケデリックス薬 内訳データ：タイプ別

  • 世界のサイケデリックス薬の市場規模実績：タイプ別 (2017-2022)
  • 世界のサイケデリックス薬の市場規模予測：タイプ別 (2023-2028)

第5章 サイケデリックス薬 内訳データ：アプリケーション別

  • 世界のサイケデリックス薬の市場規模実績：アプリケーション別 (2017-2022)
  • 世界のサイケデリックス薬の市場規模予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米のサイケデリックス薬 市場規模 (2017-2028)
  • 北米のサイケデリックス薬 市場規模：タイプ別
    • 北米のサイケデリックス薬 市場規模：タイプ別 (2017-2022)
    • 北米のサイケデリックス薬 市場規模：タイプ別 (2023-2028)
    • 北米のサイケデリックス薬の市場シェア：タイプ別 (2017-2028)
  • 北米のサイケデリックス薬 市場規模：アプリケーション別
    • 北米のサイケデリックス薬 市場規模：アプリケーション別 (2017-2022)
    • 北米のサイケデリックス薬 市場規模：アプリケーション別 (2023-2028)
    • 北米のサイケデリックス薬の市場シェア：アプリケーション別 (2017-2028)
  • 北米のサイケデリックス薬 市場規模：国別
    • 北米のサイケデリックス薬 市場規模：国別 (2017-2022)
    • 北米のサイケデリックス薬 市場規模：国別 (2023-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州のサイケデリックス薬 市場規模 (2017-2028)
  • 欧州のサイケデリックス薬 市場規模：タイプ別
    • 欧州のサイケデリックス薬 市場規模：タイプ別 (2017-2022)
    • 欧州のサイケデリックス薬 市場規模：タイプ別 (2023-2028)
    • 欧州のサイケデリックス薬の市場シェア：タイプ別 (2017-2028)
  • 欧州のサイケデリックス薬 市場規模：アプリケーション別
    • 欧州のサイケデリックス薬 市場規模：アプリケーション別 (2017-2022)
    • 欧州のサイケデリックス薬 市場規模：アプリケーション別 (2023-2028)
    • 欧州のサイケデリックス薬の市場シェア：アプリケーション別 (2017-2028)
  • 欧州のサイケデリックス薬 市場規模：国別
    • 欧州のサイケデリックス薬 市場規模：国別 (2017-2022)
    • 欧州のサイケデリックス薬 市場規模：国別 (2023-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 アジア太平洋地域

  • アジア太平洋地域 サイケデリックス薬 市場規模 (2017-2028)
  • アジア太平洋地域 サイケデリックス薬 市場規模：タイプ別
    • アジア太平洋地域 サイケデリックス薬 市場規模：タイプ別 (2017-2022)
    • アジア太平洋地域 サイケデリックス薬 市場規模：タイプ別 (2023-2028)
    • アジア太平洋地域 サイケデリックス薬の市場シェア：タイプ別 (2017-2028)
  • アジア太平洋地域 サイケデリックス薬 市場規模：アプリケーション別
    • アジア太平洋地域 サイケデリックス薬 市場規模：アプリケーション別 (2017-2022)
    • アジア太平洋地域 サイケデリックス薬 市場規模：アプリケーション別 (2023-2028)
    • アジア太平洋地域 サイケデリックス薬の市場シェア：アプリケーション別 (2017-2028)
  • アジア太平洋地域 サイケデリックス薬 市場規模：地域別
    • アジア太平洋地域 サイケデリックス薬 市場規模：地域別 (2017-2022)
    • アジア太平洋地域 サイケデリックス薬 市場規模：地域別 (2023-2028)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカのサイケデリックス薬 市場規模 (2017-2028)
  • ラテンアメリカのサイケデリックス薬 市場規模：タイプ別
    • ラテンアメリカのサイケデリックス薬 市場規模：タイプ別 (2017-2022)
    • ラテンアメリカのサイケデリックス薬 市場規模：タイプ別 (2023-2028)
    • ラテンアメリカのサイケデリックス薬の市場シェア：タイプ別 (2017-2028)
  • ラテンアメリカのサイケデリックス薬 市場規模：アプリケーション別
    • ラテンアメリカのサイケデリックス薬 市場規模：アプリケーション別 (2017-2022)
    • ラテンアメリカのサイケデリックス薬 市場規模：アプリケーション別 (2023-2028)
    • ラテンアメリカのサイケデリックス薬の市場シェア：アプリケーション別 (2017-2028)
  • ラテンアメリカのサイケデリックス薬 市場規模：国別
    • ラテンアメリカのサイケデリックス薬 市場規模：国別 (2017-2022)
    • ラテンアメリカのサイケデリックス薬 市場規模：国別 (2023-2028)
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカのサイケデリックス薬 市場規模 (2017-2028)
  • 中東・アフリカのサイケデリックス薬 市場規模：タイプ別
    • 中東・アフリカのサイケデリックス薬 市場規模：タイプ別 (2017-2022)
    • 中東・アフリカのサイケデリックス薬 市場規模：タイプ別 (2023-2028)
    • 中東・アフリカのサイケデリックス薬の市場シェア：タイプ別 (2017-2028)
  • 中東・アフリカのサイケデリックス薬 市場規模：アプリケーション別
    • 中東・アフリカのサイケデリックス薬 市場規模：アプリケーション別 (2017-2022)
    • 中東・アフリカのサイケデリックス薬 市場規模：アプリケーション別 (2023-2028)
    • 中東・アフリカのサイケデリックス薬の市場シェア：アプリケーション別 (2017-2028)
  • 中東・アフリカのサイケデリックス薬 市場規模：国別
    • 中東・アフリカのサイケデリックス薬 市場規模：国別 (2017-2022)
    • 中東・アフリカのサイケデリックス薬 市場規模：国別 (2023-2028)
    • トルコ
    • サウジアラビア
    • UAE

第11章 主要企業のプロファイル

  • COMPASS Pathways PLC
  • Pfizer
  • Eli Lilly
  • GlaxoSmithKline
  • Cybin Inc
  • Field Trip Health
  • ATAI Life Sciences
  • NUMINUS WELLNESS
  • MindMed
  • HAVN Life Sciences
  • Seelos Therapeutics
  • Jannsen
  • Acadia Pharmaceuticals
  • Intellipharmaceutics
  • Revive Therapeutics
  • Mydecine Innovations Group
  • Red Light Holland
  • Braxia Scientific
  • Mind Cure Health
  • Entheon Biomedical

第12章 アナリストによる分析/結論

第13章 付録

図表
  • Table 1. Global Psychedelic Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
  • Table 2. Key Players of Psilocybin
  • Table 3. Key Players of LSD
  • Table 4. Key Players of MDMA
  • Table 5. Key Players of DMT
  • Table 6. Key Players of Ketamine
  • Table 7. Key Players of Others
  • Table 8. Global Psychedelic Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
  • Table 9. Global Psychedelic Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
  • Table 10. Global Psychedelic Drugs Market Size by Region (2017-2022) & (US$ Million)
  • Table 11. Global Psychedelic Drugs Market Share by Region (2017-2022)
  • Table 12. Global Psychedelic Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
  • Table 13. Global Psychedelic Drugs Market Share by Region (2023-2028)
  • Table 14. Psychedelic Drugs Market Trends
  • Table 15. Psychedelic Drugs Market Drivers
  • Table 16. Psychedelic Drugs Market Challenges
  • Table 17. Psychedelic Drugs Market Restraints
  • Table 18. Global Psychedelic Drugs Revenue by Players (2017-2022) & (US$ Million)
  • Table 19. Global Psychedelic Drugs Revenue Share by Players (2017-2022)
  • Table 20. Global Top Psychedelic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2021)
  • Table 21. Ranking of Global Top Psychedelic Drugs Companies by Revenue (US$ Million) in 2021
  • Table 22. Global 5 Largest Players Market Share by Psychedelic Drugs Revenue (CR5 and HHI) & (2017-2022)
  • Table 23. Key Players Headquarters and Area Served
  • Table 24. Key Players Psychedelic Drugs Product Solution and Service
  • Table 25. Date of Enter into Psychedelic Drugs Market
  • Table 26. Mergers & Acquisitions, Expansion Plans
  • Table 27. Global Psychedelic Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 28. Global Psychedelic Drugs Revenue Market Share by Type (2017-2022)
  • Table 29. Global Psychedelic Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 30. Global Psychedelic Drugs Revenue Market Share by Type (2023-2028)
  • Table 31. Global Psychedelic Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 32. Global Psychedelic Drugs Revenue Share by Application (2017-2022)
  • Table 33. Global Psychedelic Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 34. Global Psychedelic Drugs Revenue Share by Application (2023-2028)
  • Table 35. North America Psychedelic Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 36. North America Psychedelic Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 37. North America Psychedelic Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 38. North America Psychedelic Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 39. North America Psychedelic Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 40. North America Psychedelic Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 41. Europe Psychedelic Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 42. Europe Psychedelic Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 43. Europe Psychedelic Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 44. Europe Psychedelic Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 45. Europe Psychedelic Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 46. Europe Psychedelic Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 47. Asia Pacific Psychedelic Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 48. Asia Pacific Psychedelic Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 49. Asia Pacific Psychedelic Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 50. Asia Pacific Psychedelic Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 51. Asia Pacific Psychedelic Drugs Market Size by Region (2017-2022) & (US$ Million)
  • Table 52. Asia Pacific Psychedelic Drugs Market Size by Region (2023-2028) & (US$ Million)
  • Table 53. Latin America Psychedelic Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 54. Latin America Psychedelic Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 55. Latin America Psychedelic Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 56. Latin America Psychedelic Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 57. Latin America Psychedelic Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 58. Latin America Psychedelic Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 59. Middle East and Africa Psychedelic Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 60. Middle East and Africa Psychedelic Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 61. Middle East and Africa Psychedelic Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 62. Middle East and Africa Psychedelic Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 63. Middle East and Africa Psychedelic Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 64. Middle East and Africa Psychedelic Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 65. COMPASS Pathways PLC Company Details
  • Table 66. COMPASS Pathways PLC Business Overview
  • Table 67. COMPASS Pathways PLC Psychedelic Drugs Product
  • Table 68. COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 69. COMPASS Pathways PLC Recent Developments
  • Table 70. Pfizer Company Details
  • Table 71. Pfizer Business Overview
  • Table 72. Pfizer Psychedelic Drugs Product
  • Table 73. Pfizer Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 74. Pfizer Recent Developments
  • Table 75. Eli Lilly Company Details
  • Table 76. Eli Lilly Business Overview
  • Table 77. Eli Lilly Psychedelic Drugs Product
  • Table 78. Eli Lilly Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 79. Eli Lilly Recent Developments
  • Table 80. GlaxoSmithKline Company Details
  • Table 81. GlaxoSmithKline Business Overview
  • Table 82. GlaxoSmithKline Psychedelic Drugs Product
  • Table 83. GlaxoSmithKline Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 84. GlaxoSmithKline Recent Developments
  • Table 85. Cybin Inc Company Details
  • Table 86. Cybin Inc Business Overview
  • Table 87. Cybin Inc Psychedelic Drugs Product
  • Table 88. Cybin Inc Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 89. Cybin Inc Recent Developments
  • Table 90. Field Trip Health Company Details
  • Table 91. Field Trip Health Business Overview
  • Table 92. Field Trip Health Psychedelic Drugs Product
  • Table 93. Field Trip Health Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 94. Field Trip Health Recent Developments
  • Table 95. ATAI Life Sciences Company Details
  • Table 96. ATAI Life Sciences Business Overview
  • Table 97. ATAI Life Sciences Psychedelic Drugs Product
  • Table 98. ATAI Life Sciences Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 99. ATAI Life Sciences Recent Developments
  • Table 100. NUMINUS WELLNESS Company Details
  • Table 101. NUMINUS WELLNESS Business Overview
  • Table 102. NUMINUS WELLNESS Psychedelic Drugs Product
  • Table 103. NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 104. NUMINUS WELLNESS Recent Developments
  • Table 105. MindMed Company Details
  • Table 106. MindMed Business Overview
  • Table 107. MindMed Psychedelic Drugs Product
  • Table 108. MindMed Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 109. MindMed Recent Developments
  • Table 110. HAVN Life Sciences Company Details
  • Table 111. HAVN Life Sciences Business Overview
  • Table 112. HAVN Life Sciences Psychedelic Drugs Product
  • Table 113. HAVN Life Sciences Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 114. HAVN Life Sciences Recent Developments
  • Table 115. Seelos Therapeutics Company Details
  • Table 116. Seelos Therapeutics Business Overview
  • Table 117. Seelos Therapeutics Psychedelic Drugs Product
  • Table 118. Seelos Therapeutics Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 119. Seelos Therapeutics Recent Developments
  • Table 120. Jannsen Company Details
  • Table 121. Jannsen Business Overview
  • Table 122. Jannsen Psychedelic Drugs Product
  • Table 123. Jannsen Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 124. Jannsen Recent Developments
  • Table 125. Acadia Pharmaceuticals Company Details
  • Table 126. Acadia Pharmaceuticals Business Overview
  • Table 127. Acadia Pharmaceuticals Psychedelic Drugs Product
  • Table 128. Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 129. Acadia Pharmaceuticals Recent Developments
  • Table 130. Intellipharmaceutics Company Details
  • Table 131. Intellipharmaceutics Business Overview
  • Table 132. Intellipharmaceutics Psychedelic Drugs Product
  • Table 133. Intellipharmaceutics Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 134. Intellipharmaceutics Recent Developments
  • Table 135. Revive Therapeutics Company Details
  • Table 136. Revive Therapeutics Business Overview
  • Table 137. Revive Therapeutics Psychedelic Drugs Product
  • Table 138. Revive Therapeutics Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 139. Revive Therapeutics Recent Developments
  • Table 140. Mydecine Innovations Group Company Details
  • Table 141. Mydecine Innovations Group Business Overview
  • Table 142. Mydecine Innovations Group Psychedelic Drugs Product
  • Table 143. Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 144. Mydecine Innovations Group Recent Developments
  • Table 145. Red Light Holland Company Details
  • Table 146. Red Light Holland Business Overview
  • Table 147. Red Light Holland Psychedelic Drugs Product
  • Table 148. Red Light Holland Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 149. Red Light Holland Recent Developments
  • Table 150. Braxia Scientific Company Details
  • Table 151. Braxia Scientific Business Overview
  • Table 152. Braxia Scientific Psychedelic Drugs Product
  • Table 153. Braxia Scientific Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 154. Braxia Scientific Recent Developments
  • Table 155. Mind Cure Health Company Details
  • Table 156. Mind Cure Health Business Overview
  • Table 157. Mind Cure Health Psychedelic Drugs Product
  • Table 158. Mind Cure Health Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 159. Mind Cure Health Recent Developments
  • Table 160. Entheon Biomedical Company Details
  • Table 161. Entheon Biomedical Business Overview
  • Table 162. Entheon Biomedical Psychedelic Drugs Product
  • Table 163. Entheon Biomedical Revenue in Psychedelic Drugs Business (2017-2022) & (US$ Million)
  • Table 164. Entheon Biomedical Recent Developments
  • Table 165. Research Programs/Design for This Report
  • Table 166. Key Data Information from Secondary Sources
  • Table 167. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Psychedelic Drugs Market Share by Type: 2021 VS 2028
  • Figure 2. Psilocybin Features
  • Figure 3. LSD Features
  • Figure 4. MDMA Features
  • Figure 5. DMT Features
  • Figure 6. Ketamine Features
  • Figure 7. Others Features
  • Figure 8. Global Psychedelic Drugs Market Share by Application: 2021 VS 2028
  • Figure 9. Depressive Disorders Case Studies
  • Figure 10. Post-Traumatic Stress Disorders Case Studies
  • Figure 11. Substance Abuse Disorders Case Studies
  • Figure 12. Obsessive Compulsive Disorders Case Studies
  • Figure 13. Others Case Studies
  • Figure 14. Psychedelic Drugs Report Years Considered
  • Figure 15. Global Psychedelic Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 16. Global Psychedelic Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 17. Global Psychedelic Drugs Market Share by Region: 2021 VS 2028
  • Figure 18. Global Psychedelic Drugs Market Share by Players in 2021
  • Figure 19. Global Top Psychedelic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2021)
  • Figure 20. The Top 10 and 5 Players Market Share by Psychedelic Drugs Revenue in 2021
  • Figure 21. North America Psychedelic Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 22. North America Psychedelic Drugs Market Size Market Share by Type (2017-2028)
  • Figure 23. North America Psychedelic Drugs Market Size Market Share by Application (2017-2028)
  • Figure 24. North America Psychedelic Drugs Market Size Share by Country (2017-2028)
  • Figure 25. United States Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 26. Canada Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 27. Europe Psychedelic Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 28. Europe Psychedelic Drugs Market Size Market Share by Type (2017-2028)
  • Figure 29. Europe Psychedelic Drugs Market Size Market Share by Application (2017-2028)
  • Figure 30. Europe Psychedelic Drugs Market Size Share by Country (2017-2028)
  • Figure 31. Germany Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 32. France Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 33. U.K. Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 34. Italy Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 35. Russia Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 36. Nordic Countries Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 37. Asia-Pacific Psychedelic Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 38. Asia Pacific Psychedelic Drugs Market Size Market Share by Type (2017-2028)
  • Figure 39. Asia Pacific Psychedelic Drugs Market Size Market Share by Application (2017-2028)
  • Figure 40. Asia Pacific Psychedelic Drugs Market Size Share by Region (2017-2028)
  • Figure 41. China Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 42. Japan Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 43. South Korea Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 44. Southeast Asia Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 45. India Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 46. Australia Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

  • Figure 47. Latin America Psychedelic Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 48. Latin America Psychedelic Drugs Market Size Market Share by Type (2017-2028)
  • Figure 49. Latin America Psychedelic Drugs Market Size Market Share by Application (2017-2028)
  • Figure 50. Latin America Psychedelic Drugs Market Size Share by Country (2017-2028)
  • Figure 51. Mexico Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 52. Brazil Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 53. Middle East & Africa Psychedelic Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 54. Middle East and Africa Psychedelic Drugs Market Size Market Share by Type (2017-2028)
  • Figure 55. Middle East and Africa Psychedelic Drugs Market Size Market Share by Application (2017-2028)
  • Figure 56. Middle East and Africa Psychedelic Drugs Market Size Share by Country (2017-2028)
  • Figure 57. Turkey Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 58. Saudi Arabia Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 59. UAE Psychedelic Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 60. COMPASS Pathways PLC Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 61. Pfizer Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 62. Eli Lilly Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 63. GlaxoSmithKline Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 64. Cybin Inc Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 65. Field Trip Health Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 66. ATAI Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 67. NUMINUS WELLNESS Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 68. MindMed Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 69. HAVN Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 70. Seelos Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 71. Jannsen Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 72. Acadia Pharmaceuticals Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 73. Intellipharmaceutics Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 74. Revive Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 75. Mydecine Innovations Group Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 76. Red Light Holland Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 77. Braxia Scientific Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 78. Mind Cure Health Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 79. Entheon Biomedical Revenue Growth Rate in Psychedelic Drugs Business (2017-2022)
  • Figure 80. Bottom-up and Top-down Approaches for This Report
  • Figure 81. Data Triangulation
  • Figure 82. Key Executives Interviewed
目次

This research report focuses on the Psychedelic Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Business Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Psychedelic Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Psilocybin
    • 1.2.3 LSD
    • 1.2.4 MDMA
    • 1.2.5 DMT
    • 1.2.6 Ketamine
    • 1.2.7 Others
  • 1.3 Market by Application
    • 1.3.1 Global Psychedelic Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Depressive Disorders
    • 1.3.3 Post-Traumatic Stress Disorders
    • 1.3.4 Substance Abuse Disorders
    • 1.3.5 Obsessive Compulsive Disorders
    • 1.3.6 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Psychedelic Drugs Market Perspective (2017-2028)
  • 2.2 Psychedelic Drugs Growth Trends by Region
    • 2.2.1 Psychedelic Drugs Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 Psychedelic Drugs Historic Market Size by Region (2017-2022)
    • 2.2.3 Psychedelic Drugs Forecasted Market Size by Region (2023-2028)
  • 2.3 Psychedelic Drugs Market Dynamics
    • 2.3.1 Psychedelic Drugs Industry Trends
    • 2.3.2 Psychedelic Drugs Market Drivers
    • 2.3.3 Psychedelic Drugs Market Challenges
    • 2.3.4 Psychedelic Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Psychedelic Drugs Players by Revenue
    • 3.1.1 Global Top Psychedelic Drugs Players by Revenue (2017-2022)
    • 3.1.2 Global Psychedelic Drugs Revenue Market Share by Players (2017-2022)
  • 3.2 Global Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Psychedelic Drugs Revenue
  • 3.4 Global Psychedelic Drugs Market Concentration Ratio
    • 3.4.1 Global Psychedelic Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Drugs Revenue in 2021
  • 3.5 Psychedelic Drugs Key Players Head office and Area Served
  • 3.6 Key Players Psychedelic Drugs Product Solution and Service
  • 3.7 Date of Enter into Psychedelic Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Psychedelic Drugs Breakdown Data by Type

  • 4.1 Global Psychedelic Drugs Historic Market Size by Type (2017-2022)
  • 4.2 Global Psychedelic Drugs Forecasted Market Size by Type (2023-2028)

5 Psychedelic Drugs Breakdown Data by Application

  • 5.1 Global Psychedelic Drugs Historic Market Size by Application (2017-2022)
  • 5.2 Global Psychedelic Drugs Forecasted Market Size by Application (2023-2028)

6 North America

  • 6.1 North America Psychedelic Drugs Market Size (2017-2028)
  • 6.2 North America Psychedelic Drugs Market Size by Type
    • 6.2.1 North America Psychedelic Drugs Market Size by Type (2017-2022)
    • 6.2.2 North America Psychedelic Drugs Market Size by Type (2023-2028)
    • 6.2.3 North America Psychedelic Drugs Market Share by Type (2017-2028)
  • 6.3 North America Psychedelic Drugs Market Size by Application
    • 6.3.1 North America Psychedelic Drugs Market Size by Application (2017-2022)
    • 6.3.2 North America Psychedelic Drugs Market Size by Application (2023-2028)
    • 6.3.3 North America Psychedelic Drugs Market Share by Application (2017-2028)
  • 6.4 North America Psychedelic Drugs Market Size by Country
    • 6.4.1 North America Psychedelic Drugs Market Size by Country (2017-2022)
    • 6.4.2 North America Psychedelic Drugs Market Size by Country (2023-2028)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Psychedelic Drugs Market Size (2017-2028)
  • 7.2 Europe Psychedelic Drugs Market Size by Type
    • 7.2.1 Europe Psychedelic Drugs Market Size by Type (2017-2022)
    • 7.2.2 Europe Psychedelic Drugs Market Size by Type (2023-2028)
    • 7.2.3 Europe Psychedelic Drugs Market Share by Type (2017-2028)
  • 7.3 Europe Psychedelic Drugs Market Size by Application
    • 7.3.1 Europe Psychedelic Drugs Market Size by Application (2017-2022)
    • 7.3.2 Europe Psychedelic Drugs Market Size by Application (2023-2028)
    • 7.3.3 Europe Psychedelic Drugs Market Share by Application (2017-2028)
  • 7.4 Europe Psychedelic Drugs Market Size by Country
    • 7.4.1 Europe Psychedelic Drugs Market Size by Country (2017-2022)
    • 7.4.2 Europe Psychedelic Drugs Market Size by Country (2023-2028)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 Asia-Pacific

  • 8.1 Asia-Pacific Psychedelic Drugs Market Size (2017-2028)
  • 8.2 Asia-Pacific Psychedelic Drugs Market Size by Type
    • 8.2.1 Asia-Pacific Psychedelic Drugs Market Size by Type (2017-2022)
    • 8.2.2 Asia-Pacific Psychedelic Drugs Market Size by Type (2023-2028)
    • 8.2.3 Asia-Pacific Psychedelic Drugs Market Share by Type (2017-2028)
  • 8.3 Asia-Pacific Psychedelic Drugs Market Size by Application
    • 8.3.1 Asia-Pacific Psychedelic Drugs Market Size by Application (2017-2022)
    • 8.3.2 Asia-Pacific Psychedelic Drugs Market Size by Application (2023-2028)
    • 8.3.3 Asia-Pacific Psychedelic Drugs Market Share by Application (2017-2028)
  • 8.4 Asia-Pacific Psychedelic Drugs Market Size by Region
    • 8.4.1 Asia-Pacific Psychedelic Drugs Market Size by Region (2017-2022)
    • 8.4.2 Asia-Pacific Psychedelic Drugs Market Size by Region (2023-2028)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Psychedelic Drugs Market Size (2017-2028)
  • 9.2 Latin America Psychedelic Drugs Market Size by Type
    • 9.2.1 Latin America Psychedelic Drugs Market Size by Type (2017-2022)
    • 9.2.2 Latin America Psychedelic Drugs Market Size by Type (2023-2028)
    • 9.2.3 Latin America Psychedelic Drugs Market Share by Type (2017-2028)
  • 9.3 Latin America Psychedelic Drugs Market Size by Application
    • 9.3.1 Latin America Psychedelic Drugs Market Size by Application (2017-2022)
    • 9.3.2 Latin America Psychedelic Drugs Market Size by Application (2023-2028)
    • 9.3.3 Latin America Psychedelic Drugs Market Share by Application (2017-2028)
  • 9.4 Latin America Psychedelic Drugs Market Size by Country
    • 9.4.1 Latin America Psychedelic Drugs Market Size by Country (2017-2022)
    • 9.4.2 Latin America Psychedelic Drugs Market Size by Country (2023-2028)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Psychedelic Drugs Market Size (2017-2028)
  • 10.2 Middle East & Africa Psychedelic Drugs Market Size by Type
    • 10.2.1 Middle East & Africa Psychedelic Drugs Market Size by Type (2017-2022)
    • 10.2.2 Middle East & Africa Psychedelic Drugs Market Size by Type (2023-2028)
    • 10.2.3 Middle East & Africa Psychedelic Drugs Market Share by Type (2017-2028)
  • 10.3 Middle East & Africa Psychedelic Drugs Market Size by Application
    • 10.3.1 Middle East & Africa Psychedelic Drugs Market Size by Application (2017-2022)
    • 10.3.2 Middle East & Africa Psychedelic Drugs Market Size by Application (2023-2028)
    • 10.3.3 Middle East & Africa Psychedelic Drugs Market Share by Application (2017-2028)
  • 10.4 Middle East & Africa Psychedelic Drugs Market Size by Country
    • 10.4.1 Middle East & Africa Psychedelic Drugs Market Size by Country (2017-2022)
    • 10.4.2 Middle East & Africa Psychedelic Drugs Market Size by Country (2023-2028)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 COMPASS Pathways PLC
    • 11.1.1 COMPASS Pathways PLC Company Details
    • 11.1.2 COMPASS Pathways PLC Business Overview
    • 11.1.3 COMPASS Pathways PLC Psychedelic Drugs Introduction
    • 11.1.4 COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.1.5 COMPASS Pathways PLC Recent Developments
  • 11.2 Pfizer
    • 11.2.1 Pfizer Company Details
    • 11.2.2 Pfizer Business Overview
    • 11.2.3 Pfizer Psychedelic Drugs Introduction
    • 11.2.4 Pfizer Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.2.5 Pfizer Recent Developments
  • 11.3 Eli Lilly
    • 11.3.1 Eli Lilly Company Details
    • 11.3.2 Eli Lilly Business Overview
    • 11.3.3 Eli Lilly Psychedelic Drugs Introduction
    • 11.3.4 Eli Lilly Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.3.5 Eli Lilly Recent Developments
  • 11.4 GlaxoSmithKline
    • 11.4.1 GlaxoSmithKline Company Details
    • 11.4.2 GlaxoSmithKline Business Overview
    • 11.4.3 GlaxoSmithKline Psychedelic Drugs Introduction
    • 11.4.4 GlaxoSmithKline Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.4.5 GlaxoSmithKline Recent Developments
  • 11.5 Cybin Inc
    • 11.5.1 Cybin Inc Company Details
    • 11.5.2 Cybin Inc Business Overview
    • 11.5.3 Cybin Inc Psychedelic Drugs Introduction
    • 11.5.4 Cybin Inc Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.5.5 Cybin Inc Recent Developments
  • 11.6 Field Trip Health
    • 11.6.1 Field Trip Health Company Details
    • 11.6.2 Field Trip Health Business Overview
    • 11.6.3 Field Trip Health Psychedelic Drugs Introduction
    • 11.6.4 Field Trip Health Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.6.5 Field Trip Health Recent Developments
  • 11.7 ATAI Life Sciences
    • 11.7.1 ATAI Life Sciences Company Details
    • 11.7.2 ATAI Life Sciences Business Overview
    • 11.7.3 ATAI Life Sciences Psychedelic Drugs Introduction
    • 11.7.4 ATAI Life Sciences Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.7.5 ATAI Life Sciences Recent Developments
  • 11.8 NUMINUS WELLNESS
    • 11.8.1 NUMINUS WELLNESS Company Details
    • 11.8.2 NUMINUS WELLNESS Business Overview
    • 11.8.3 NUMINUS WELLNESS Psychedelic Drugs Introduction
    • 11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.8.5 NUMINUS WELLNESS Recent Developments
  • 11.9 MindMed
    • 11.9.1 MindMed Company Details
    • 11.9.2 MindMed Business Overview
    • 11.9.3 MindMed Psychedelic Drugs Introduction
    • 11.9.4 MindMed Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.9.5 MindMed Recent Developments
  • 11.10 HAVN Life Sciences
    • 11.10.1 HAVN Life Sciences Company Details
    • 11.10.2 HAVN Life Sciences Business Overview
    • 11.10.3 HAVN Life Sciences Psychedelic Drugs Introduction
    • 11.10.4 HAVN Life Sciences Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.10.5 HAVN Life Sciences Recent Developments
  • 11.11 Seelos Therapeutics
    • 11.11.1 Seelos Therapeutics Company Details
    • 11.11.2 Seelos Therapeutics Business Overview
    • 11.11.3 Seelos Therapeutics Psychedelic Drugs Introduction
    • 11.11.4 Seelos Therapeutics Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.11.5 Seelos Therapeutics Recent Developments
  • 11.12 Jannsen
    • 11.12.1 Jannsen Company Details
    • 11.12.2 Jannsen Business Overview
    • 11.12.3 Jannsen Psychedelic Drugs Introduction
    • 11.12.4 Jannsen Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.12.5 Jannsen Recent Developments
  • 11.13 Acadia Pharmaceuticals
    • 11.13.1 Acadia Pharmaceuticals Company Details
    • 11.13.2 Acadia Pharmaceuticals Business Overview
    • 11.13.3 Acadia Pharmaceuticals Psychedelic Drugs Introduction
    • 11.13.4 Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.13.5 Acadia Pharmaceuticals Recent Developments
  • 11.14 Intellipharmaceutics
    • 11.14.1 Intellipharmaceutics Company Details
    • 11.14.2 Intellipharmaceutics Business Overview
    • 11.14.3 Intellipharmaceutics Psychedelic Drugs Introduction
    • 11.14.4 Intellipharmaceutics Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.14.5 Intellipharmaceutics Recent Developments
  • 11.15 Revive Therapeutics
    • 11.15.1 Revive Therapeutics Company Details
    • 11.15.2 Revive Therapeutics Business Overview
    • 11.15.3 Revive Therapeutics Psychedelic Drugs Introduction
    • 11.15.4 Revive Therapeutics Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.15.5 Revive Therapeutics Recent Developments
  • 11.16 Mydecine Innovations Group
    • 11.16.1 Mydecine Innovations Group Company Details
    • 11.16.2 Mydecine Innovations Group Business Overview
    • 11.16.3 Mydecine Innovations Group Psychedelic Drugs Introduction
    • 11.16.4 Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.16.5 Mydecine Innovations Group Recent Developments
  • 11.17 Red Light Holland
    • 11.17.1 Red Light Holland Company Details
    • 11.17.2 Red Light Holland Business Overview
    • 11.17.3 Red Light Holland Psychedelic Drugs Introduction
    • 11.17.4 Red Light Holland Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.17.5 Red Light Holland Recent Developments
  • 11.18 Braxia Scientific
    • 11.18.1 Braxia Scientific Company Details
    • 11.18.2 Braxia Scientific Business Overview
    • 11.18.3 Braxia Scientific Psychedelic Drugs Introduction
    • 11.18.4 Braxia Scientific Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.18.5 Braxia Scientific Recent Developments
  • 11.19 Mind Cure Health
    • 11.19.1 Mind Cure Health Company Details
    • 11.19.2 Mind Cure Health Business Overview
    • 11.19.3 Mind Cure Health Psychedelic Drugs Introduction
    • 11.19.4 Mind Cure Health Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.19.5 Mind Cure Health Recent Developments
  • 11.20 Entheon Biomedical
    • 11.20.1 Entheon Biomedical Company Details
    • 11.20.2 Entheon Biomedical Business Overview
    • 11.20.3 Entheon Biomedical Psychedelic Drugs Introduction
    • 11.20.4 Entheon Biomedical Revenue in Psychedelic Drugs Business (2017-2022)
    • 11.20.5 Entheon Biomedical Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer